Format

Send to

Choose Destination
Front Immunol. 2017 Jan 27;8:44. doi: 10.3389/fimmu.2017.00044. eCollection 2017.

Defective IL-23/IL-17 Axis Protects p47phox-/- Mice from Colon Cancer.

Author information

1
Department of Pediatrics, University Clinic 'Carl Gustav Carus' Dresden, Dresden, Germany; pharmazentrum frankfurt/ZAFES, Goethe University, Frankfurt, Germany.
2
pharmazentrum frankfurt/ZAFES, Goethe University , Frankfurt , Germany.
3
I. Medical Clinic, University of Erlangen-Nuremberg , Erlangen , Germany.
4
pharmazentrum frankfurt/ZAFES, Goethe University, Frankfurt, Germany; Department of Internal Medicine 1, Goethe University, Frankfurt, Germany.
5
Bristol-Myers Squibb GmbH & Co. KGaA , Munich , Germany.
6
Department of Pathology, University Clinic 'Carl Gustav Carus' Dresden , Dresden , Germany.
7
German Red Cross Blood Service, Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany; Department of Medicine/Hematology, University of Washington, Seattle, WA, USA.
8
Department of Pediatrics, University Clinic 'Carl Gustav Carus' Dresden , Dresden , Germany.

Abstract

In the colon, a sophisticated balance between immune reaction and tolerance is absolutely required. Dysfunction may lead to pathologic phenotypes ranging from chronic inflammatory processes to cancer development. Two prominent modulators of colon inflammation are represented by the closely related cytokines interleukin (IL)-12 and IL-23, which initiate adaptive Th1 and Th17 immune responses, respectively. In this study, we investigated the impact of the NADPH oxidase protein p47phox, which negatively regulates IL-12 in dendritic cells, on colon cancer development in a colitis-associated colon cancer model. Initially, we found that IL-12-/- mice developed less severe colitis but are highly susceptible to colon cancer. By contrast, p47phox-/- mice showed lower tumor scores and fewer high grade tumors than wild-type (WT) littermates. Treatment with toll-like receptor 9 ligand CpG2216 significantly enhanced colitis in p47phox-/- mice, whereas tumor growth was simultaneously reduced. In tumor tissue of p47phox-/- mice, the IL-23/IL-17 axis was crucially hampered. IL-23p19 protein expression in tumor tissue correlated with tumor stage. Reconstitution of WT mice with IL-23p19-/- bone marrow protected these mice from colon cancer, whereas transplantation of WT hematopoiesis into IL-23p19-/- mice increased the susceptibility to tumor growth. Our study strengthens the divergent role of IL-12 and IL-23 in colon cancer development. With the characterization of p47phox as a novel modulator of both cytokines our investigation introduces a promising new target for antitumor strategies.

KEYWORDS:

DSS/AOM; IL-17; IL-23; IL23p19 knockout mouse; chronic colitis; colon cancer; p47phox

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center